MYLUNG Consortium Study Protocol 2 (NCT05644808)
Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Prospective RWE Study (MYLUNG Consortium: Part 2)
🩺 Plain-English Summary (8th-Grade Level)
This pragmatic study looks to quantify the testing timeline, operational barriers, and outcomes of biomarker-guided therapy in a large, community-based, and largely unselected patient population with early stage and advanced stage, treatment-naive non-small cell lung cancer, whether squamous or non-squamous.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (5 items) and avoid the listed exclusions (4 items).
Location: Southern Cancer Center, PC — Daphne, Alabama
Age range: 18 Years
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Stage IA at the time of enrollment
- Subjects with small cell lung cancer
- Subjects with Unknown primary tumor origin
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (18 Sites)
- Southern Cancer Center, PC — Daphne, Alabama
- Rocky Mountain Cancer Center — Denver, Colorado
- Woodlands Medical Specialists, PA — Pensacola, Florida
- Illinois Cancer Specialists — Niles, Illinois
- Maryland Oncology Hematology, P.A. — Silver Spring, Maryland
- Minnesota Oncology Hematology, P.A. — Minneapolis, Minnesota
- New York Oncology Hematology, P.C. — Albany, New York
- Oncology Hematology Care Clinical Trials, LLC — Cincinnati, Ohio
- Willamette Valley Cancer Institute and Research Center — Eugene, Oregon
- Texas Oncology - West Texas — Abilene, Texas
- Texas Oncology- DFWW — Arlington, Texas
- Texas Oncology-Dallas Presbyterian Hospital — Dallas, Texas
- Texas Oncology-Baylor Charles A. Sammons Cancer Center — Dallas, Texas
- Texas Oncology - Fort Worth Cancer Center — Fort Worth, Texas
- Texas Oncology-McAllen — McAllen, Texas
- Texas Oncology- Northeast Texas — Tyler, Texas
- Virginia Cancer Specialists, PC — Fairfax, Virginia
- Virginia Oncology Associates — Newport News, Virginia
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Carcinoma, Non-Small-Cell Lung
- A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) — Des Moines, Iowa
- A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) — Gilbert, Arizona
- THIO Sequenced With Cemiplimab in Advanced NSCLC — Birmingham, Alabama
- A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions — Duarte, California
- Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study — La Jolla, California
Explore by condition: All Carcinoma, Non-Small-Cell Lung clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.